122 related articles for article (PubMed ID: 36958671)
21. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
[TBL] [Abstract][Full Text] [Related]
22. Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
Jain M; Carlson G; Cook W; Morrow L; Petrone M; White NE; Wang T; Naylor J; Ambery P; Lee C; Hirshberg B
Diabetologia; 2019 Mar; 62(3):373-386. PubMed ID: 30593607
[TBL] [Abstract][Full Text] [Related]
23. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
25. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
[TBL] [Abstract][Full Text] [Related]
26. Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509, a soluble guanylyl cyclase activator, in healthy volunteers: Results from two randomized controlled trials.
Wong D; Seitz F; Bauer V; Giessmann T; Schulze F
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; ():. PubMed ID: 38789635
[TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
[TBL] [Abstract][Full Text] [Related]
28. Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes.
Kiewiet RM; van Aken MO; van der Weerd K; Uitterlinden P; Themmen AP; Hofland LJ; de Rijke YB; Delhanty PJ; Ghigo E; Abribat T; van der Lely AJ
Eur J Endocrinol; 2009 Oct; 161(4):567-73. PubMed ID: 19628651
[TBL] [Abstract][Full Text] [Related]
29. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults.
Silverman MH; Duggan S; Bardelli G; Sadler B; Key C; Medlock M; Reynolds L; Wallner B
J Prev Alzheimers Dis; 2022; 9(4):635-645. PubMed ID: 36281667
[TBL] [Abstract][Full Text] [Related]
30. Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics.
Moschetti V; Schlecker C; Wind S; Goetz S; Schmitt H; Schultz A; Liesenfeld KH; Wunderlich G; Desch M
Clin Drug Investig; 2018 Aug; 38(8):737-750. PubMed ID: 29846887
[TBL] [Abstract][Full Text] [Related]
31. Acute effects of acylated and unacylated ghrelin on total and high molecular weight adiponectin inmorbidly obese subjects.
Kiewiet RM; Hazell MJ; van Aken MO; van der Weerd K; Visser JA; Themmen AP; van der Lely AJ
J Endocrinol Invest; 2011 Jun; 34(6):434-8. PubMed ID: 20959720
[TBL] [Abstract][Full Text] [Related]
32. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
33. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
35. Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects.
Royalty JE; Konradsen G; Eskerod O; Wulff BS; Hansen BS
J Clin Pharmacol; 2014 Apr; 54(4):394-404. PubMed ID: 24166760
[TBL] [Abstract][Full Text] [Related]
36. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
37. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Knop FK; Aroda VR; do Vale RD; Holst-Hansen T; Laursen PN; Rosenstock J; Rubino DM; Garvey WT;
Lancet; 2023 Aug; 402(10403):705-719. PubMed ID: 37385278
[TBL] [Abstract][Full Text] [Related]
38. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
Allas S; Caixàs A; Poitou C; Coupaye M; Thuilleaux D; Lorenzini F; Diene G; Crinò A; Illouz F; Grugni G; Potvin D; Bocchini S; Delale T; Abribat T; Tauber M
PLoS One; 2018; 13(1):e0190849. PubMed ID: 29320575
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of a polyphenolic extract (Lippia citriodora and Hibiscus sabdariffa) on appetite regulation in overweight and obese grade I population: an 8-week randomized, double-blind, cross-over, placebo-controlled trial.
Serna A; Marhuenda J; Arcusa R; Pérez-Piñero S; Sánchez-Macarro M; García-Muñoz AM; Victoria-Montesinos D; Cánovas F; López-Román FJ
Eur J Nutr; 2022 Mar; 61(2):825-841. PubMed ID: 34591168
[TBL] [Abstract][Full Text] [Related]
40. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
Kinzler ER; Pantaleon C; Iverson M; Aigner S
Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
